Debdutta Bandyopadhyay

Cadila Healthcare (India) — India

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index2.0kcitations40works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Epigenetics and DNA Methylation(7), Cancer-related Molecular Pathways(7), Telomeres, Telomerase, and Senescence(7), Receptor Mechanisms and Signaling(7), Diabetes Treatment and Management(5)

Publications40 total

Discovery of ZYDG2: A potent, selective, and safe GPR40 agonist for treatment of type 2 diabetes
Journal of Pharmacology and Experimental Therapeutics·2025· 1 cited
Design, synthesis and biological evaluation of novel pyrazolo-pyrimidin-amines as potent and selective BTK inhibitors
Bioorganic Chemistry·2022· 3 cited
ZYKR1, a novel, potent, and peripherally selective kappa opioid receptor agonist reduces visceral pain and pruritus in animal models
European Journal of Pharmacology·2022· 7 cited
Optimisation of momelotinib with improved potency and efficacy as pan-JAK inhibitor
Bioorganic & Medicinal Chemistry Letters·2022· 7 citedOpen Access
Discovery of novel, potent and orally efficacious inhibitor of neutral amino acid transporter B0AT1 (SLC6A19)
Bioorganic & Medicinal Chemistry Letters·2021· 14 cited
Syntheses, biological evaluation of some novel substituted benzoic acid derivatives bearing hydrazone as linker
Research on Chemical Intermediates·2021· 8 cited
Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes
Bioorganic & Medicinal Chemistry·2021· 17 citedOpen Access
Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor
Bioorganic & Medicinal Chemistry Letters·2020· 21 citedOpen Access
ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
Pharmacology Research & Perspectives·2020· 13 citedOpen Access
Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors
Bioorganic Chemistry·2020· 7 cited
Discovery of <i>N</i>-Cyano-sulfoximineurea Derivatives as Potent and Orally Bioavailable NLRP3 Inflammasome Inhibitors
ACS Medicinal Chemistry Letters·2020· 46 citedOpen Access
Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kδ selective inhibitors
Bioorganic & Medicinal Chemistry Letters·2019· 2 citedOpen Access
ZYDG2, a Potent, Selective, and Safe GPR40 Agonist for Treatment of Type 2 Diabetes
Diabetes·2018· 3 cited
Scientific and Regulatory Considerations in the Development of in Vitro Techniques for Toxicology
Elsevier eBooks·2017· 10 cited
Identification of an Orally Efficacious GPR40/FFAR1 Receptor Agonist
ACS Medicinal Chemistry Letters·2016· 9 citedOpen Access
Discovery of Orally Active, Potent, and Selective Benzotriazole‐Based PTP1B Inhibitors
ChemMedChem·2011· 25 citedOpen Access
Design, synthesis and biological evaluation of γ-lactam hydroxamate based TACE inhibitors
MedChemComm·2011· 9 cited
Design and synthesis of novel 3-hydroxy-cyclobut-3-ene-1,2-dione derivatives as thyroid hormone receptor β (TR-β) selective ligands
Bioorganic & Medicinal Chemistry Letters·2008· 8 citedOpen Access
Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi
Aging Cell·2007· 81 citedOpen Access
Epigenetic Therapies of Cancer
Current Cancer Therapy Reviews·2006· 2 cited
page 1 of 2Next →

Frequent Co-authors

Mukul R. Jain(15), Estela E. Medrano(12), Ranjit C. Desai(9), Poonam Giri(7), Rajesh Bahekar(7), Rajiv Sharma(5), Dipam Patel(5), Hoshang Patel(5), Jeevan Kumar(5), Krishnarup Ghoshdastidar(5), Rajesh Sundar(5), Elise S. Bales(4), Jogeswar Mahapatra(4), Amit Joharapurkar(4), Harilal Patel(4), Pankaj Patel(4), Suresh Giri(4), Jigar Desai(4), Anasua B. Kusari(3), Jyotirmoy Kusari(3)